Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hospital staff antibody study tracks COVID-19 immunity over a year

NCT ID NCT04426006

Knowledge-focused Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how many hospital workers had COVID-19 antibodies and how long they lasted. Over 500 staff at a French cancer center gave blood samples and answered questionnaires at the start, 3 months, and 12 months. The goal was to understand immune response in people who may be exposed to the virus at work.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help answer how long COVID-19 antibodies last in healthcare workers and guide infection control policies.
What could go wrong
This is an observational study, not a treatment trial. It only measures antibodies and cannot predict protection from future infection or severe disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

526 people

The number who actually took part.

Started

Jun 2020

Finished

Oct 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult 18 years-old and older. 2. Person in employment (on fixed-term or permanent contracts) since (at least) March 17th, 2020, the date of national implementation of containment measures in response to the COVID-19 pandemic. 3. Signed informed consent. 4. Person affiliated to a French social security regimen in accordance with Article 1121-11 of the French Public Health Code). Exclusion Criteria: 1. Report of known active SARS-CoV-2 infection within 10 days prior to the date of signing the consent. Known active SARS-CoV-2 infection is defined as a positive result on a diagnostic RT-PCR test. 2. Presence of known symptoms suggestive of COVID-19 within 10 days prior to the date of signing consent: fever, fatigue, dry cough, shortness of breath, loss of taste and/or smell, headache, body aches, aches and pains, conjunctivitis or colds, digestive disorders (vomiting, diarrhea). 3. A person who is unable to follow and comply with research procedures due to geographical, social or psychological reasons. 4. Pregnant or breastfeeding woman. 5. Person deprived of their liberty, incapable or incapable of giving their consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder COVID-19 disease serum sickness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV2 Serum; disease

Contacts and locations

Locations

  • Institut Bergonié

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.